Recruiting

VRT106 and Chemotherapy for Resectable Pancreatic Cancer

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Oncolytic virus VRT106

+ Chemotherapy

Drug
Who is being recruted

Digestive System Diseases+5

+ Digestive System Neoplasms

+ Endocrine System Diseases

From 18 to 75 Years
+11 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 1 & 2
Interventional
Study Start: March 2025
See protocol details

Summary

Principal SponsorGuangdong Provincial People's Hospital
Study ContactChen RF Prof.
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: March 17, 2025

Actual date on which the first participant was enrolled.

This study is exploring a new treatment option for people with resectable pancreatic cancer, which means the cancer can be surgically removed. Researchers are testing a drug called VRT106 along with standard chemotherapy to see if this combination works well and is safe. This is important because pancreatic cancer can be difficult to treat, and finding effective treatments could improve outcomes for those affected by this disease. Participants in the study will first go through a screening period that lasts up to 28 days to ensure they qualify for the study. They will then receive the treatment, which includes VRT106 and chemotherapy. After completing the treatment, participants will be monitored for any side effects or safety issues for 28 days. Additionally, researchers will check on the participants' overall health every three months to track survival outcomes. This approach helps ensure that the treatment is not only effective but also safe for patients.

Official TitleA Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
NCT06758544
Principal SponsorGuangdong Provincial People's Hospital
Study ContactChen RF Prof.
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

18 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 75 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Digestive System DiseasesDigestive System NeoplasmsEndocrine System DiseasesEndocrine Gland NeoplasmsNeoplasmsNeoplasms by SitePancreatic DiseasesPancreatic Neoplasms

Criteria

6 inclusion criteria required to participate
Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures.
Males and females at 18-75 years of age, inclusive, at the Screening Visit.
Have a clinical diagnosis of pancreatic cancer.
An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
Show More Criteria
5 exclusion criteria prevent from participating
Prior treatment with other oncolytic virus or systemic therapy for pancreatic cancer.
Previous allogeneic hematopoietic stem cell transplantation or organ transplantation.
Immunocompromised patients.
Known alcohol or drug dependency.
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
VRT106 combination with chemotherapy

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Guangdong Provincial People's Hospital

Guangzhou, ChinaOpen Guangdong Provincial People's Hospital in Google Maps
Recruiting
One Study Center